Siemens Healthineers stock: RBC lifts target to EUR 48
Published on 10/20/2026 at 17:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target reset on October 15
- RBC raised its Siemens Healthineers target from EUR 45.00 to EUR 48.00 on October 15, 2026.
- Fiscal 2026 revenue growth guidance moved from 4.50-5.00 percent to 3.50-4.00 percent on July 31, 2026.
- Siemens Healthineers stock costs EUR 41.53 at Lang & Schwarz on October 20, 2026 at 5:08 p.m. CEST, 1.22 percent above the Xetra close of October 19, 2026.
- Fourth-quarter results are scheduled for November 5, 2026.
Siemens Healthineers raised its analyst profile after RBC lifted the price target from EUR 45.00 to EUR 48.00 on October 15, 2026, while keeping its Outperform rating. The move followed the launch of the Accela radiation therapy system, according to MarketScreener. Siemens Healthineers was trading at EUR 41.53 at Lang & Schwarz on October 20, 2026 at 5:08 p.m. CEST, up 1.22 percent versus the Xetra close of October 19, 2026 at EUR 41.03.
RBC target leaves 15.58 percent upside
The new RBC target stands 15.58 percent above the Lang & Schwarz price. That comparison puts the analyst view above the current quotation, but it does not remove the execution issues already visible in the latest operating update.
Siemens Healthineers is scheduled to publish its fourth-quarter results and hold its analyst call on November 5, 2026, according to the company's Siemens Healthineers investor-relations calendar.
Q3 guidance fell to 3.50-4.00 percent
In the Q3 fiscal 2026 call on July 31, 2026, Siemens Healthineers reported equipment book-to-bill of 1.27 and lowered fiscal 2026 revenue growth guidance from 4.50-5.00 percent to 3.50-4.00 percent. The company also raised adjusted earnings-per-share guidance by EUR 0.15 because of tariff refunds, as reported in the Yahoo Finance transcript.
Valuation stays near the middle
Siemens Healthineers had a market capitalization of EUR 46.5 billion and a price-to-earnings ratio of 20.99 as of October 20, 2026. Its 52-week range was EUR 32.81 to EUR 49.71, leaving the stock 16.46 percent below the high and 26.57 percent above the low.
The next reporting date gives investors a defined checkpoint for testing the RBC view. The Q3 update showed that the equipment order ratio remained above 1.00, while the reduced revenue outlook placed greater weight on execution in the final quarter.
Trading remains above the prior close
Siemens Healthineers was trading at EUR 41.53 at Lang & Schwarz on October 20, 2026 at 5:08 p.m. CEST, 1.22 percent above the Xetra close of October 19, 2026 at EUR 41.03. The current price remains below the 52-week high of EUR 49.71.
The further course of trading is shown by the continuously updated real-time quote of Siemens Healthineers stock.
Siemens Healthineers key figures
- Company: Siemens Healthineers AG
- ISIN: DE000SHL1006
- WKN: SHL100
- Ticker: SHL
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 20, 2026, 5:08 p.m. CEST): EUR 41.53
- Change versus Xetra close: plus 1.22 percent
- Xetra close (October 19, 2026): EUR 41.03
- Market capitalization: EUR 46.5 billion (as of October 20, 2026)
- 52-week range: EUR 32.81-EUR 49.71 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report DAX.
